Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
November 04 2021 - 8:30AM
Business Wire
Omeros Corporation (NASDAQ: OMER) today announced that the
company will issue its third quarter financial results for the
period ended September 30, 2021, on Tuesday, November 9, 2021,
after the market closes. Omeros management will host a conference
call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m.
Pacific Time) to discuss the financial results as well as recent
developments and highlights.
Conference Call Details
To access the live conference call via phone, please dial (844)
831-4029 from the United States and Canada or (920) 663-6278
internationally. The participant passcode is 7744465. Please dial
in approximately 10 minutes prior to the start of the call. A
telephone replay will be available for one week following the call
and may be accessed by dialing (855) 859-2056 from the United
States and Canada or (404) 537-3406 internationally. The replay
passcode is 7744465.
To access the live and subsequently archived webcast of the
conference call, go to Omeros’ website at
https://investor.omeros.com/upcoming-events.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed
to discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting inflammation, immunologic diseases (e.g.,
complement-mediated diseases and cancers) and central nervous
system disorders. Its commercial product OMIDRIA® (phenylephrine
and ketorolac intraocular solution) 1%/0.3% continues to gain
market share in cataract surgery. Omeros’ lead MASP-2 inhibitor
narsoplimab targets the lectin pathway of complement, and Omeros is
seeking FDA approval of narsoplimab for the treatment of
hematopoietic stem cell transplant-associated thrombotic
microangiopathy. Additional narsoplimab programs are focused on
other complement-mediated disorders, including IgA nephropathy,
atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’
inhibitor of MASP-3, the key activator of the alternative pathway
of complement, is in a Phase 1 clinical trial, and the company’s
PDE7 inhibitor program OMS527, targeting addiction and movement
disorders, has successfully completed a Phase 1 trial. Omeros’
pipeline holds a diverse group of preclinical programs including a
proprietary-asset-enabled antibody-generating technology and a
proprietary GPCR platform through which it controls 54 GPCR drug
targets and their corresponding compounds. One of these novel
targets, GPR174, modulates a new cancer immunity axis recently
discovered by Omeros, and the company is advancing GPR174-targeting
antibodies and small-molecule inhibitors.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211104005469/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024